Relates to Antibodies that bind to Human angiopoyetina\u20132 (ANG2), comprising: a) a light chain (LC) comprising complementarity determining regions lcdr1, lcdr2 and lcdr3 consisting in the Peptide sequences kasqdvyiava (SEQ ID no: 8)Ywastrdt (SEQ ID no: 9) and hqyssyppt (SEQ ID no: 10), respectively and (b) (HC) comprising heavy chain complementarity determining regions hcdr1, hcdr2 and hcdr3 consisting in the Peptide sequences gysftdynmv (SEQ ID no: 11), yidpynggtgynqkfeg (SEQ ID no: 12) and artrdrydvwyfdv ( SEQ ID no: 13) respectively.In a Preferred aspect, the light chain (LC) comprises a variable region of light chain (lcvr) Peptide whose sequence is as described in SEQ ID no: 3 heavy chain (HC) and a variable region of heavy chain (hcvr) Peptide whose sequence is as described in SEQ ID no: 1.In a Preferred aspect, the Antibody comprises a light chain (LC) and heavy chain (HC) whose Peptide sequences are as described in SEQ ID no: 2 and SEQ ID no: 2, respectively.It also relates to pharmaceutical compositions comprising such Antibodies in Mammalian Cells that Express One of the preferred Antibody, and to methods for producing Said Antibody preferred for cultivation of Mammalian Cells that Express it.These Antibodies are useful for the treatment of breast cancer, ovarian cancer, gastric cancer, colorectal cancer or hepatocellular carcinomaSe refiere a anticuerpos que se unen a angiopoyetina–2 humana (Ang2), que comprenden: a) una cadena ligera (LC) que comprende regiones determinantes de complementariedad LCDR1, LCDR2 y LCDR3 que consisten en las secuencias peptidicas KASQDVYIAVA (SEQ ID NO: 8), YWASTRDT (SEQ ID NO: 9) y HQYSSYPPT (SEQ ID NO: 10) respectivamente y b) una cadena pesada (HC) que comprende regiones determinantes de complementariedad HCDR1, HCDR2 y HCDR3 que consisten en las secuencias peptidicas GYSFTDYNMV (SEQ ID NO: 11), YIDPYNGGTGYNQKFEG (SEQ ID NO: 12) y ARTRDRYDVWYFDV (SEQ ID NO: 13) respectivamente. En un aspecto preferido, la cadena ligera
